ACOR Loses Ampyra Patent Appeal, XBIT Awaits Data, AYTU Touches New Low



A phase II clinical study evaluating Bermekimab in patients with moderate to severe Hidradenitis Suppurativa is underway. — A physician-sponsored …



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *